CGTX — Cognition Therapeutics Share Price
0.000.00%
Last trade - 00:00- $71.76m
- $41.84m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.93 | ||
| Price to Tang. Book | 2.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -202.94% | ||
| Return on Equity | -79.69% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.
Directors
- Lisa Ricciardi PRE (60)
- Susan Catalano CFD
- James O'Brien CFO
- Stephen Sands DRC
- Peggy Wallace DRC
- Ellen Richstone IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 21st, 2007
- Public Since
- October 8th, 2021
- No. of Shareholders
- 277
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 39,000,152
- Address
- Suite 261, 2403 Sidney Street, PITTSBURGH, 15203
- Web
- https://cogrx.com/
- Phone
- +1 4127701621
- Auditors
- Ernst & Young LLP
Upcoming Events for CGTX
Cognition Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Cognition Therapeutics Inc Earnings Release
Similar to CGTX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Cognition Therapeutics share price?
As of Today at 19:05 UTC, shares in Cognition Therapeutics are trading at $1.84. This share price information is delayed by 15 minutes.
How has the Cognition Therapeutics share price performed this year?
Shares in Cognition Therapeutics last closed at $1.84 and the price had moved by +9.52% over the past 365 days. In terms of relative price strength the Cognition Therapeutics share price has underperformed the S&P500 Index by -8.86% over the past year.
What are the analyst and broker recommendations for Cognition Therapeutics?
The overall consensus recommendation for Cognition Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cognition Therapeutics dividend yield?
Cognition Therapeutics does not currently pay a dividend.
Does Cognition Therapeutics pay a dividend?
Cognition Therapeutics does not currently pay a dividend.
When does Cognition Therapeutics next pay dividends?
Cognition Therapeutics does not currently pay a dividend.
How do I buy Cognition Therapeutics shares?
To buy shares in Cognition Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cognition Therapeutics?
As of the previous close price of $1.84, shares in Cognition Therapeutics had a market capitalisation of $71.76m.
Where are Cognition Therapeutics shares listed?
Here are the trading details for Cognition Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CGTX
What kind of share is Cognition Therapeutics?
Based on an overall assessment of its quality, value and momentum Cognition Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cognition Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Cognition Therapeutics is $6.67. That is 262.5% above the last closing price of $1.84.
Analysts covering Cognition Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.98 for the next financial year.
What is the trend in the Cognition Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cognition Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +21.09%.
As of the last closing price of $1.84, shares in Cognition Therapeutics were trading +10.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cognition Therapeutics PE Ratio?
The Cognition Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cognition Therapeutics?
Cognition Therapeutics' management team is headed by:
- Lisa Ricciardi - PRE
- Susan Catalano - CFD
- James O'Brien - CFO
- Stephen Sands - DRC
- Peggy Wallace - DRC
- Ellen Richstone - IND